Wait, Can Nitrous Oxide Alleviate Depression?

PLUS, guides on liquid culture, Albino A+, and a story about growing mushrooms in sub-zero temperatures.

 

TOGETHER WITH

Good morning and welcome to the first Drop In of 2026! We're kicking things off with a story about a newly published review looking at the antidepressant effects of nitrous oxide. (Ice cold fatty anyone? 🎈)

A new meta-analysis suggests that nitrous may deliver rapid (even if it's short-lived) relief from depressive symptoms with effects showing up within hours. But can the fleeting lift of gas be sustained beyond that initial burst? We talk about that and more in today’s story. You can find that immediately below!

If you keep scrolling, you’ll find guides on liquid culture, Albino A+ , and a piece on how AI is showing up in psychedelic medicine.

Stay weird this year 🖖,

Mary Carreón
Editor-in-Chief

Together With SANTA

Unlock your flow state with Santa 🍄

January is about momentum, not resolution burnout. For those looking to unlock flow state without overstimulation, Santa offers a compelling alternative to alcohol or coffee overload.

Formulated with muscimol expertly extracted from Amanita alongside a light dose of caffeine, Santa is designed to support relaxed focus — the kind of clarity where ideas connect, work feels fluid, and presence comes naturally. It’s not about pushing harder or checking out; it’s about finding a steadier rhythm that allows flow to emerge.

For the post-holiday reset, Santa fits seamlessly into workdays, creative sessions, or intentional evenings — helping you unlock flow state without the crash, jitters, or edge that often comes with traditional stimulants. Thoughtful, modern, and culture-forward, Santa speaks to a new generation of overstimulated minds looking for functional tools that enhance how they feel, think, and create.

Trust us, you’ll like it. Use code DB10 for 10% off your order and try SANTA today.

Can Nitrous Oxide Relieve Depression?

The scientific revolution of psychedelics has done one thing: given all of the popular party drugs 15 minutes of clinical legitimacy, in which each substance is platformed and taken out of the context of addiction and abuse, and presented to us as an antidote to the mental health crisis. Now, nitrous oxide, colloquially known as “whippits,” “nos,” “gas,” or “ice cold fatties,” is getting a moment to shine beyond the balloon-studded parking lots outside of Phish or Dead & Co. shows.

According to a new systematic review and meta-analysis published in eBioMedicine, researchers examined seven clinical trials (with a total of 247 participants) looking at the effects of nitrous on major depressive disorder, treatment-resistant depression, and bipolar depression. The analysis found that a single inhaled session of 50% nitrous oxide was associated with a measurable reduction in depressive symptoms within hours. The researchers note that the effects were brief and mild, but the question remains whether relief can be sustained.

“N2O demonstrates rapid, reproducible antidepressant effects in early-phase trials,” says Kiranpreet Gill, a leading author of the review. “Its future clinical value depends on whether these effects can be sustained over time through optimised dosing and extended/repeated use. Improved trial design, outcome standardisation, and population diversity are required to clarify its full potential for the treatment of depression.

To better understand, the authors gathered and analyzed existing research rather than running a new trial. They reviewed clinical trials, exploratory studies, and published study protocols to understand what the current data says. Their search covered major scientific databases and included studies published through June 2025.

They found that nitrous oxide was administered by inhalation at concentrations of either 25% or 50%. Some studies tested a single session, while others examined repeated sessions over several weeks. Control conditions varied and included air, oxygen, or midazolam (a short-acting benzodiazepine), depending on the study design.

When the researchers combined data from three trials that tested a single session of 50% nitrous oxide, they found one consistent pattern: Depressive symptoms were significantly reduced two hours after inhalation and again at 24 hours. However, when symptoms were assessed one week later, the pooled results no longer showed a statistically significant difference compared to placebo.

“Evidence mapping showed that most trials are early-phase and focused on short-term outcomes in adults with MDD and TRD,” the study’s authors write.

Safety-wise, the paper describes adverse events as generally manageable — often things like nausea, dizziness, headache, and transient dissociation — showing up during or soon after inhalation and resolving on their own. Across trials, 25% nitrous oxide tended to be better tolerated than 50%, even as researchers continue to debate which dose (and schedule) offers the best balance between impact and comfort.

“Adverse events decreased with lower doses,” the review says. “Direct comparisons of the risk of AEs between doses suggested improved tolerability with 25% N2O compared to 50%.”

The authors’ bottom line is cautious: nitrous oxide looks promising as a fast-acting intervention, but its real-world value will hinge on whether researchers can stretch that early relief into something sturdier, through optimized dosing, longer follow-up, and more standardized trial design across more diverse patient groups.

So, will nitrous make it out of Shakedown parking lots and into clinical settings where people can access it formally? It’s impossible to know for sure, but stay tuned for our coverage, in which we discuss the possibility of whippits entering the alternative therapy machine.

 

Sneak Peek

What Science Actually Says About the Stoned Ape Theory

When Terence McKenna first floated the Stoned Ape Theory in the early '90s, it landed somewhere between philosophical provocation and a drugged-out, fringe hypothesis, embraced by psychedelic thinkers and dismissed by evolutionary scientists.

Now, his younger brother, ethnobotanist Dennis McKenna, argues that the ground beneath the theory has shifted. Advances in neuroscience, epigenetics, and evolutionary biology — fields that scarcely existed in their current form when Food of the Gods was published — have complicated long-held assumptions about how brains change, and how quickly. In this week’s feature, we examine why McKenna believes these developments move the Stoned Ape Theory out of the realm of psychedelic fantasy and into a more uncomfortable, unresolved space at the edges of mainstream science, where evidence is suggestive but incomplete, and where the origins of human consciousness remain, stubbornly, an open question.

Upgrade your subscription here to read the full story by Mattha Busby on Friday.

& More Must-Reads

  • Liquid culture is the quiet workhorse of mushroom cultivation. It’s a deceptively simple technique that can dramatically speed up growth, boost yields, and turn a few milliliters of mycelium into a near-limitless supply for growers ready to level up. Read more.

  • As winters grow harsher, farmers in northern India are finding ways to grow mushrooms in sub-zero temperatures and turning fungi into a year-round lifeline. Read more.

  • Albino A+ mushrooms may look ghostly, but they’re anything but mythical. This grower’s guide breaks down what they actually are (hint: not truly albino), why cultivators love them, and what to know before growing or consuming one of the most popular Psilocybe cubensis varieties around. Read more.

  • Using supercomputers and machine learning, scientists are designing an entirely new class of psychedelic-inspired drugs meant to heal the mind without the trip, and to rewrite how psychiatry itself works. Read more.

DoubleBlind Digs

  • READ: DoubleBlind just published its first book—and DoubleBlind+ members get a free copy of The DoubleBlind Guide to Psychedelics, a beautifully designed, safety-forward handbook covering substances, dosage, contraindications, and what to expect. Learn more here.

  • MEET: Santa — an Amanita Muscaria tonic crafted for calm, focus, and clean energy. No CBD, psilocybin, kratom, or alcohol—just clarity without the crash. Use DB10 for 10% off.

  • DONATE: The Indigenous Medicine Conservation Fund (IMC Fund) has appointed a 100% Indigenous Board of Directors, marking a historic step toward ensuring that the protection of sacred medicines, lands, and knowledge is led by the Peoples who have safeguarded them for millennia. This new governance model redefines global philanthropy by centering Indigenous leadership, sovereignty, and spirituality in conservation. Donate here.

Together With SANTA

Santa is the next generation of functional energy.

Blending muscimol expertly extracted from Amanita with green caffeine, it supports productive clarity without jitters, stress or crash.

Ideal for easing into the new year, Santa speaks to a new generation of overstimulated minds looking for functional tools that enhance how they feel, think, and create.

Trust us, you’ll like it. Use code DB10 for 10% off your order and try Santa today.

Around the Web

  • At an annual New Year’s ritual in Lima, Peruvian shamans made global headlines by predicting illness for Donald Trump. Reuters has the story.

  • Quitting alcohol didn’t dull Andrew M. Weisse’s edge, he writes; it revealed what drinking had been quietly taking from him all along. Read his story here.

  • A biotech betting on non-hallucinogenic psychedelics just locked down a sweeping new patent that will expand its claim over hundreds of mescaline-inspired molecules designed to rewire the brain without the trip. Read more.

How was today's Drop In?

Login or Subscribe to participate in polls.

💌 If you loved this email, forward it to a psychonaut in your life.

Reply

or to participate.